Hui Jun Lim1, Philip Crowe, Jia-Lin Yang. 1. Adult Cancer Program, Sarcoma and Nano-oncology Group, Faculty of Medicine, Lowy Cancer Research Centre, Prince of Wales Clinical School, University of New South Wales, Room 209, Randwick, Sydney, NSW, 2052, Australia.
Abstract
PURPOSE: PTEN is an essential tumour suppressor gene which encodes a phosphatase protein that antagonises the PI3K/Akt/mTOR antiapoptotic pathway. Impairment of this tumour suppressor pathway potentially becomes a causal factor for development of malignancies. This review aims to assess current understanding of mechanisms of dysfunction involving the PI3K/PTEN/Akt/mTOR pathway linked to tumorigenesis and evaluate the evidence for targeted therapy directed at this signalling axis. METHODS: Relevant articles in scientific databases were identified using a combination of search terms, including "malignancies", "targeted therapy", "PTEN", and "combination therapy". These databases included Medline, Embase, Cochrane Review, Pubmed, and Scopus. RESULTS: PI3K/PTEN expression is frequently deregulated in a majority of malignancies through genetic, epigenetic, and post-transcriptional modifications. This contributes to the upregulation of the PI3K/Akt/mTOR pathway which has been the focus of intense clinical studies. Targeted agents aimed at this pathway offer a novel treatment approach in a variety of haematologic malignancies and solid tumours. Compared to single-agent use, greater response rates were obtained in combination regimens, supporting further investigation of suitable drug combinations in a broad spectrum of malignancies. CONCLUSION: Activation of the PI3K/PTEN/Akt/mTOR pathway is implicated both in the pathogenesis of malignancies and development of resistance to anticancer therapies. Therefore, PI3K/Akt/mTOR inhibitors are a promising therapeutic option, in association with systemic cytotoxic and biological therapies, to enable sustained clinical outcomes in cancer treatment. Therapeutic strategies could be tailored according to appropriate biomarkers and patient-specific mutation profiles to maximise benefit of combination therapies.
PURPOSE:PTEN is an essential tumour suppressor gene which encodes a phosphatase protein that antagonises the PI3K/Akt/mTOR antiapoptotic pathway. Impairment of this tumour suppressor pathway potentially becomes a causal factor for development of malignancies. This review aims to assess current understanding of mechanisms of dysfunction involving the PI3K/PTEN/Akt/mTOR pathway linked to tumorigenesis and evaluate the evidence for targeted therapy directed at this signalling axis. METHODS: Relevant articles in scientific databases were identified using a combination of search terms, including "malignancies", "targeted therapy", "PTEN", and "combination therapy". These databases included Medline, Embase, Cochrane Review, Pubmed, and Scopus. RESULTS: PI3K/PTEN expression is frequently deregulated in a majority of malignancies through genetic, epigenetic, and post-transcriptional modifications. This contributes to the upregulation of the PI3K/Akt/mTOR pathway which has been the focus of intense clinical studies. Targeted agents aimed at this pathway offer a novel treatment approach in a variety of haematologic malignancies and solid tumours. Compared to single-agent use, greater response rates were obtained in combination regimens, supporting further investigation of suitable drug combinations in a broad spectrum of malignancies. CONCLUSION: Activation of the PI3K/PTEN/Akt/mTOR pathway is implicated both in the pathogenesis of malignancies and development of resistance to anticancer therapies. Therefore, PI3K/Akt/mTOR inhibitors are a promising therapeutic option, in association with systemic cytotoxic and biological therapies, to enable sustained clinical outcomes in cancer treatment. Therapeutic strategies could be tailored according to appropriate biomarkers and patient-specific mutation profiles to maximise benefit of combination therapies.
Authors: Andrew J Armstrong; George J Netto; Michelle A Rudek; Susan Halabi; David P Wood; Patricia A Creel; Kelly Mundy; S Lindsay Davis; Ting Wang; Roula Albadine; Luciana Schultz; Alan W Partin; Antonio Jimeno; Helen Fedor; Phillip G Febbo; Daniel J George; Robin Gurganus; Angelo M De Marzo; Michael A Carducci Journal: Clin Cancer Res Date: 2010-05-25 Impact factor: 12.531
Authors: Antje Krohn; Tobias Diedler; Lia Burkhardt; Pascale-Sophie Mayer; Colin De Silva; Marie Meyer-Kornblum; Darja Kötschau; Pierre Tennstedt; Joseph Huang; Clarissa Gerhäuser; Malte Mader; Stefan Kurtz; Hüseyin Sirma; Fred Saad; Thomas Steuber; Markus Graefen; Christoph Plass; Guido Sauter; Ronald Simon; Sarah Minner; Thorsten Schlomm Journal: Am J Pathol Date: 2012-06-13 Impact factor: 4.307
Authors: Elizabeth R Plimack; Tingting Tan; Yu-Ning Wong; Margaret M von Mehren; Lois Malizzia; Susan K Roethke; Samuel Litwin; Tianyu Li; Gary R Hudes; Naomi B Haas Journal: Oncologist Date: 2014-03-27
Authors: A M Martelli; P L Tazzari; C Evangelisti; F Chiarini; W L Blalock; A M Billi; L Manzoli; J A McCubrey; L Cocco Journal: Curr Med Chem Date: 2007 Impact factor: 4.530
Authors: Jeroen Buijsen; Guido Lammering; Rob L H Jansen; Geerard L Beets; Jaap Wals; Meindert Sosef; Marien O Den Boer; Jeroen Leijtens; Robert G Riedl; Jan Theys; Philippe Lambin Journal: Radiother Oncol Date: 2013-05-03 Impact factor: 6.280
Authors: Hiromasa Yamamoto; Hisayuki Shigematsu; Masaharu Nomura; William W Lockwood; Mitsuo Sato; Naoki Okumura; Junichi Soh; Makoto Suzuki; Ignacio I Wistuba; Kwun M Fong; Huei Lee; Shinichi Toyooka; Hiroshi Date; Wan L Lam; John D Minna; Adi F Gazdar Journal: Cancer Res Date: 2008-09-01 Impact factor: 12.701
Authors: Michael F Berger; Michael S Lawrence; Francesca Demichelis; Yotam Drier; Kristian Cibulskis; Andrey Y Sivachenko; Andrea Sboner; Raquel Esgueva; Dorothee Pflueger; Carrie Sougnez; Robert Onofrio; Scott L Carter; Kyung Park; Lukas Habegger; Lauren Ambrogio; Timothy Fennell; Melissa Parkin; Gordon Saksena; Douglas Voet; Alex H Ramos; Trevor J Pugh; Jane Wilkinson; Sheila Fisher; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jonathan W Simons; Naoki Kitabayashi; Theresa Y MacDonald; Philip W Kantoff; Lynda Chin; Stacey B Gabriel; Mark B Gerstein; Todd R Golub; Matthew Meyerson; Ashutosh Tewari; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway Journal: Nature Date: 2011-02-10 Impact factor: 49.962
Authors: William C Reinhold; Margot Sunshine; Sudhir Varma; James H Doroshow; Yves Pommier Journal: Clin Cancer Res Date: 2015-06-05 Impact factor: 12.531
Authors: Karin Hoppe-Seyler; Felicitas Bossler; Claudia Lohrey; Julia Bulkescher; Frank Rösl; Lars Jansen; Arnulf Mayer; Peter Vaupel; Matthias Dürst; Felix Hoppe-Seyler Journal: Proc Natl Acad Sci U S A Date: 2017-01-23 Impact factor: 11.205
Authors: Jonathan Noujaim; Khin Thway; Zia Bajwa; Ayeza Bajwa; Robert G Maki; Robin L Jones; Charles Keller Journal: Front Oncol Date: 2015-08-17 Impact factor: 6.244